Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma.
In the video series, Cheson and Park discussed the following:
- Overview of relapsed/refractory follicular lymphoma and available treatment options
- Tazemetostat trial data and propensity score-matched analysis
- Role of tazemetostat treatment moving forward
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
